Martin Welschof, CEO of Affitech, said: “I thank Oyvin Broymer, who took over the chairmanship of Affitech in 2002 at a time of major strategic change and has skillfully guided us to our current position. I look forward to working closely with Keith McCullagh, whose experience in building successful biotech companies will be of great value as we enter the next phase of Affitech’s growth and development.”
Affitech has also announced that Thomas von Rueden has retired as a director, having completed his term of office.
Affitech intends to focus its future development on building a pipeline of proprietary therapeutic antibody product candidates, through both in-house research and development and alliances with other companies.